Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Air Products and Chemicals, Inc.

APD
Materials · Specialty Chemicals

Air Products and Chemicals, Inc.'s price has outrun its earnings. +4.6% in a year against EPS −110.3% — the market is paying now for delivery later.

The sharpest disagreement: the price moved +4.6% in a year while annual EPS moved −110.3% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a confirmed uptrend (2 weeks in) while the P/E sits at the 74th percentile of its own 4-year range. Underneath, the last four quarters read improving, and 119% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$295
+4.6% 1Y
P/E
31.1×
74th pctile
of its own 4-year range
Revenue (Mar 26)
$3.2 B
+8.6% YoY
Profit (Mar 26)
$0.7 B
Operating margin
23.7%
+103.5 pp YoY
ROE
0%
FY25
ROIC
−1.5%
vs WACC 6.8% → −8.3 pp
Cash conversion
119%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Air Products and Chemicals, Inc. trades at $295, in a confirmed uptrend and 2 weeks into that stage. That is +6.6% against its own 200-day average. It sits at 74% of a 52-week range of $240 to $314. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (14 weeks and counting).

Today the stock is in a confirmed uptrend — week 2 of stage 2. At $295 it trades +6.6% versus its 200-day average and sits at 74% of its 52-week range ($240–$314).

Aug 26: $295 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+6.6% versus the 200-day line, week 2 of stage 2
Price50-day avg200-day avg
S1S4S3S2S1S4S3$344$311$278$244$211$$295$277Jul 23Apr 24Jan 25Oct 25Aug 26
S1S4S3S2S1S4S3$344$311$278$244$211$$295$277Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +104% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (14 weeks and counting; last ahead the week of 2026-05-01) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Air Products and Chemicals, Inc. trades at 31.1× P/E, at the pricey end of its own range (74th percentile). Its long-run median P/E is 27.4×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 31.1× is at the pricey end of its own range (74th percentile), against a long-run median of 27.4× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 31.1× vs a 27.4× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.3-year window; loss-period spikes above 42× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (74th percentile)
P/EMedianEPS (TTM) (quarterly)
44.1×$18.636.7×$13.929.3×$9.321.9×$4.614.4×$0.0×$31.19×$9Apr 22Apr 23May 24May 25Aug 26
44.1×$18.636.7×$13.929.3×$9.321.9×$4.614.4×$0.0×$31.19×$9Apr 22May 24Aug 26
PEG 2.49 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
4.2×3.4×2.5×1.6×0.8××2.49×Sep 21Sep 22Dec 23Mar 25Jun 26
4.2×3.4×2.5×1.6×0.8××2.49×Sep 21Dec 23Jun 26
P/E
31.1×
74th percentile of 4y
PEG
2.13
as reported

🚨 Why the multiple sits where it does: over the past year annual EPS moved −110.3% against a +4.6% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +1.2%/yr price move, ~−1.3%/yr came from earnings growth and ~+2.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Air Products and Chemicals, Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 6.4% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue −0.5% in FY25, profit −109.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
25%81%17%29%9.6%−22%1.7%−73%−6.2%−124%%%−0.5%−109%FY21FY23FY25
25%81%17%29%9.6%−22%1.7%−73%−6.2%−124%%%−0.5%−109%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit accelerating
RevenueProfitEPS
9.7%81%5.1%30%0.4%−22%−4.2%−73%−8.8%−125%%%3.6%36.1%37.4%Jun 23Sep 24Mar 26
9.7%81%5.1%30%0.4%−22%−4.2%−73%−8.8%−125%%%3.6%36.1%37.4%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
11%7.1%3.6%0.0%−3.4%%6.4%Jun 23Dec 23Sep 24Jun 25Mar 26
11%7.1%3.6%0.0%−3.4%%6.4%Jun 23Sep 24Mar 26
Revenue growth
Stuck low
latest +3.6% · span −7.5% to +8.4%
Profit growth
Rising
latest +36.1% · span −109.0% to +66.1%
EPS growth
Rising
latest +37.4% · span −110.4% to +67.0%
ROCE
Falling
latest 6.4% · span −2.4%–9.6%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−0.5%−1.8%
Stock price+4.6%+1.2%+0.3%+7.0%
Revenue YoY (Mar 26)
+8.6%
latest quarter vs a year ago
Revenue 10y
3.9%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

43.7/100 — rank 20 of 29 in Specialty Chemicals · 58% evidence confidence

Air Products and Chemicals, Inc. scores 43.7 out of 100 against the 29 companies it is compared with in Specialty Chemicals, ranking 20. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17 + 9.5 + 10.1 + 7.1 = 43.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Air Products and Chemicals, Inc. reported $3.2 B of revenue in the Mar 26 quarter, +8.6% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 3.9% a year. The last full year, FY25, came in at $12.0 B. The last four reported quarters add to $12.5 B.

FY25 revenue came in at $12.0 B (−0.5% on the year), capping 4 years at 3.9% compound. The latest quarter (Mar 26) printed $3.2 B, +8.6% year on year — the 2nd consecutive quarter of year-over-year growth.

FY25 revenue $12.0 B (−0.5% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
3.9% a year over 4 years
RevenueYoY growth
1425%1017%6.99.6%3.41.7%0.0−6.2%$ B%$12B−0.5%FY21FY23FY25
1425%1017%6.99.6%3.41.7%0.0−6.2%$ B%$12B−0.5%FY21FY23FY25
Mar 26: $3.2 B (+8.6% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Revenue (quarterly)YoY growth
3.410%2.64.6%1.7−1.0%0.9−6.6%0.0−12%$ B%$3B8.6%Jun 23Sep 24Mar 26
3.410%2.64.6%1.7−1.0%0.9−6.6%0.0−12%$ B%$3B8.6%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +3.7% growth against the decade's 3.9% — the current year is running in line with its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +3.6% over the last 4 quarters against +1.3%/yr over the last 8 — stabilising; TTM profit +36.1% vs −7.3%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Air Products and Chemicals, Inc.'s operating margin is 23.7% in the Mar 26 quarter, +103.5 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −7.3% to 36.9%. The current quarter sits inside that band.

The latest quarter's operating margin is 23.7%, +103.5 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −7.3%–36.9%.

Why the margin moved: operating margin went +103.5 pp year on year while gross margin went +1.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: −7.3% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −7.3–36.9% band over 5 years
operating marginYoY change (pp)
40%22%28%4.2%15%−14%2.0%−31%−11%−49%%%−7.3%−44.2%FY21FY23FY25
40%22%28%4.2%15%−14%2.0%−31%−11%−49%%%−7.3%−44.2%FY21FY23FY25
Mar 26: 23.7% operating margin (+103.5 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
88%120%43%60%−2.0%0.0%−47%−59%−92%−118%%%23.7%103.5%Jun 23Sep 24Mar 26
88%120%43%60%−2.0%0.0%−47%−59%−92%−118%%%23.7%103.5%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Air Products and Chemicals, Inc. earned $0.7 B of net profit in the Mar 26 quarter. The full FY25 year was a loss of $0.3 B. That is 22.7% of the quarter's revenue. The same quarter a year earlier lost $1.7 B. 1 of the last 12 reported quarters were loss-making.

Mar 26 profit was $0.7 B, null year on year. On the full year, FY25 printed $−0.3 B (−109.0%).

FY25 profit $−0.3 B (−109.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
4.281%3.030%1.8−21%0.5−72%−0.7−123%$ B%$−0B−109%FY21FY23FY25
4.281%3.030%1.8−21%0.5−72%−0.7−123%$ B%$−0B−109%FY21FY23FY25
Mar 26: $0.7 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
2.3231%1.261%0.1−108%−1.0−277%−2.0−447%$ B%$1B6.2%Jun 23Sep 24Mar 26
2.3231%1.261%0.1−108%−1.0−277%−2.0−447%$ B%$1B6.2%Jun 23Sep 24Mar 26

Pace comparison, last four quarters: profit −30.2% vs revenue +3.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 119% of Air Products and Chemicals, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.3 B of operating cash against $−0.3 B of profit. After $7.0 B of capital spending, $−3.8 B was left as free cash.

FY25: operating cash of $3.3 B against reported profit of $−0.3 B, leaving free cash of $−3.8 B after $7.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 119% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $3.3 B vs profit $−0.3 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
119% of 3-year profit arrived as cash
Operating cashNet profitFree cash
4.52.30.0−2.2−4.4$ B$3B$−0B$−4BFY21FY23FY25
4.52.30.0−2.2−4.4$ B$3B$−0B$−4BFY21FY23FY25
Jun 26: operating cash $1.3 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.413,604%1.19,964%0.76,325%0.42,685%0.0−955%$ B%$1B153%Sep 23Dec 24Jun 26
1.413,604%1.19,964%0.76,325%0.42,685%0.0−955%$ B%$1B153%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Air Products and Chemicals, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $18.0 B over the last 3 years. Averaged over those years that is 49.8% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $18.0 B over the last 3 fiscal years.

FY25: capex $7.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
7.65.73.81.90.0$ B$7BFY21FY23FY25
7.65.73.81.90.0$ B$7BFY21FY23FY25
Jun 26: capex $1.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
2.30.51.7−0.11.1−0.60.6−1.20.0−1.7$ B$ B$1B$0BSep 23Dec 24Jun 26
2.30.51.7−0.11.1−0.60.6−1.20.0−1.7$ B$ B$1B$0BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Air Products and Chemicals, Inc. earns a ROE of −2% in FY25. Return on invested capital clears the cost of that capital by −8.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −2.9% net margin on 0.29× asset turns.

FY25 ROE is −2%.

🚨 Why the return is what it is — the wiring (FY25): −2.9% net margin × 0.29× asset turns × 2.37× balance-sheet leverage ≈ −2.0% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: −1.5% − 6.8% = a −8.3 pp spread. The 6.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE −2% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 6.8% cost of capital used on this page.
the full ladder
ROEROIC (annual)WACC
23%16%9.4%2.7%−3.9%%−2%−2.1%FY21FY23FY25
23%16%9.4%2.7%−3.9%%−2%−2.1%FY21FY23FY25
Jun 26: ROIC −0.9% (TTM) vs WACC 6.8% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
26%18%11%3.0%−4.6%%−0.9%−0.2%Sep 23Dec 24Jun 26
26%18%11%3.0%−4.6%%−0.9%−0.2%Sep 23Dec 24Jun 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Air Products and Chemicals, Inc. paid $7.18 per share over the last four reported quarters, up 1.1% on a year ago. The most recent declaration was $1.81 for Mar 26. Against the current price of $295 that is a trailing yield of 2.44%, measured on dividends already paid rather than on a forecast.

Air Products and Chemicals, Inc. paid $7.18 per share across the last four reported quarters, most recently $1.81 for Mar 26. That is up 1.1% against the same quarter a year earlier. Against the current price of $295 the trailing twelve months work out to 2.44% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 10 quarters on file.
latest $1.81 (Mar 26)
Dividend per share
2.01.51.00.50.0$ B$2BJun 23Mar 24Dec 24Jun 25Mar 26
2.01.51.00.50.0$ B$2BJun 23Dec 24Mar 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Air Products and Chemicals, Inc. carries total debt of $18.2 B against shareholder equity of $16.6 B as of Jun 26, a debt-to-equity of 1.09. On the annual view that ratio went from 0.54 in FY21 to 1.06 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $18.2 B against shareholder equity of $16.6 B — a debt-to-equity of 1.09. On the annual view, debt-to-equity went from 0.54 (FY21) to 1.06 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $18.3 B at 1.06× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
201.1×151.0×9.90.8×4.90.6×0.00.5×$ B×$18B1.06×FY21FY23FY25
201.1×151.0×9.90.8×4.90.6×0.00.5×$ B×$18B1.06×FY21FY23FY25
Jun 26: debt $18.2 B, debt-to-equity 1.09 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
201.1×151.0×9.90.9×5.00.8×0.00.7×$ B×$18B1.09×Sep 23Dec 24Jun 26
201.1×151.0×9.90.9×5.00.8×0.00.7×$ B×$18B1.09×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

1.9% of Air Products and Chemicals, Inc.'s tradable float is currently sold short — the crowd is not positioned against this stock. At typical trading volumes those positions would take about 2.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 1.9% of the float is sold short, and at typical trading volumes it would take about 2.6 days to buy those positions back. The crowd is not positioned against this stock. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
1.9%
of the tradable float
Days to cover
2.6
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Air Products and Chemicals, Inc.: the Z-score reads 2.40. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.40 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.40.

15 · Related companies · Specialty Chemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1NewMarket CorporationNEU 61.9/100Thin evidence · provisional58% evidence BREAKING OUT 16.9/35 Revenue — · PAT — · OPM change -1.4 pp 45% evidence 16.1/25 ROCE 5.5% · OPM 21.4% 76% evidence 11.4/20 P/E 17× · PEG — 15% evidence 17.5/20 RS sector 5.4% · RS bench 8.6% · 1Y 20.4%12 of 12 weeks ahead 100% evidence
Exact sum: 16.9 + 16.1 + 11.4 + 17.5 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Sociedad Química y Minera de Chile S.A.SQM 61.7/100Mixed-positive evidence81% evidence ASLEEP 28.8/35 Revenue 18.3% · PAT 48.4% · OPM change 17.4 pp 83% evidence 15.8/25 ROCE 6.3% · OPM 41% 76% evidence 15.1/20 P/E 28.4× · PEG 0.81 65% evidence 2.0/20 RS sector -9.7% · RS bench -8.3% · 1Y 62.4%0 of 12 weeks ahead 100% evidence
Exact sum: 28.8 + 15.8 + 15.1 + 2 = 61.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.7% and the one-year return is 62.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3WD-40 CompanyWDFC 61.3/100Thin evidence · provisional58% evidence TURNING 21.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 17.4/25 ROCE 10.8% · OPM 16.3% 76% evidence 10.2/20 P/E 30.4× · PEG — 15% evidence 12.4/20 RS sector -3.7% · RS bench -1.4% · 1Y 7.5%5 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 17.4 + 10.2 + 12.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Sensient Technologies CorporationSXT 60.7/100Thin evidence · provisional58% evidence FADING 20.4/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence 12.8/25 ROCE 3.8% · OPM 15.3% 76% evidence 9.8/20 P/E 33.2× · PEG — 15% evidence 17.7/20 RS sector 7.9% · RS bench 10.5% · 1Y 9%8 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 12.8 + 9.8 + 17.7 = 60.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5Quaker Chemical CorporationKWR 57.5/100Thin evidence · provisional58% evidence BREAKING OUT 21.5/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence 8.3/25 ROCE 1.7% · OPM 7% 76% evidence 10.5/20 P/E 28.3× · PEG — 15% evidence 17.2/20 RS sector 6% · RS bench 8.7% · 1Y 36.6%7 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 8.3 + 10.5 + 17.2 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Axalta Coating Systems Ltd.AXTA 56.2/100Thin evidence · provisional58% evidence BREAKING OUT 15.3/35 Revenue — · PAT — · OPM change -2.3 pp 45% evidence 11.7/25 ROCE 2.8% · OPM 11.6% 76% evidence 10.8/20 P/E 21.1× · PEG — 15% evidence 18.4/20 RS sector 6.4% · RS bench 9.2% · 1Y 32.5%7 of 12 weeks ahead 100% evidence
Exact sum: 15.3 + 11.7 + 10.8 + 18.4 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Ashland Inc.ASH 54.2/100Thin evidence · provisional58% evidence BREAKING OUT 18.8/35 Revenue — · PAT — · OPM change -2.5 pp 45% evidence 7.0/25 ROCE 1% · OPM 8.1% 76% evidence 8.9/20 P/E 57.8× · PEG — 15% evidence 19.5/20 RS sector 10.3% · RS bench 12.9% · 1Y 39%9 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 7 + 8.9 + 19.5 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8The Sherwin-Williams CompanySHW 53.8/100Thin evidence · provisional58% evidence TURNING 18.7/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence 15.5/25 ROCE 7.1% · OPM 14.2% 76% evidence 10.0/20 P/E 31.7× · PEG — 15% evidence 9.6/20 RS sector -6.6% · RS bench -4% · 1Y 2.7%1 of 12 weeks ahead 100% evidence
Exact sum: 18.7 + 15.5 + 10 + 9.6 = 53.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9H.B. Fuller CompanyFUL 53.0/100Mixed-positive evidence85% evidence BASING 22.1/35 Revenue -0.6% · PAT 80.6% · OPM change 1.2 pp 95% evidence 10.9/25 ROCE 2.6% · OPM 12.3% 76% evidence 16.1/20 P/E 19× · PEG 0.5 65% evidence 3.9/20 RS sector -14.3% · RS bench -12.2% · 1Y 4.8%2 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 10.9 + 16.1 + 3.9 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10International Flavors & Fragrances Inc.IFF 52.4/100Mixed-positive evidence64% evidence ASLEEP 21.5/35 Revenue -5.6% · PAT — · OPM change 41.8 pp 62% evidence 7.2/25 ROCE 1.2% · OPM 10% 76% evidence 10.6/20 P/E 22.2× · PEG — 15% evidence 13.1/20 RS sector 0% · RS bench 2.2% · 1Y 27.3%1 of 12 weeks ahead 100% evidence
Exact sum: 21.5 + 7.2 + 10.6 + 13.1 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Eastman Chemical CompanyEMN 52.4/100Thin evidence · provisional58% evidence ASLEEP 18.6/35 Revenue — · PAT — · OPM change -4.6 pp 45% evidence 13.3/25 ROCE 4.8% · OPM 8.6% 76% evidence 11.2/20 P/E 17.4× · PEG — 15% evidence 9.3/20 RS sector -5.5% · RS bench -3.5% · 1Y 19.9%0 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 13.3 + 11.2 + 9.3 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Avient CorporationAVNT 52.2/100Mixed-positive evidence64% evidence ASLEEP 21.8/35 Revenue 1.3% · PAT 56.9% · OPM change 11.2 pp 62% evidence 9.1/25 ROCE 1.9% · OPM 11.3% 76% evidence 10.9/20 P/E 21.1× · PEG — 15% evidence 10.4/20 RS sector -4.6% · RS bench -2.6% · 1Y 16.2%0 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 9.1 + 10.9 + 10.4 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Balchem CorporationBCPC 52.2/100Thin evidence · provisional58% evidence TURNING 18.6/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.6/25 ROCE 3.8% · OPM 20.5% 76% evidence 9.9/20 P/E 33.2× · PEG — 15% evidence 9.1/20 RS sector -5.8% · RS bench -3.6% · 1Y 9.7%0 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 14.6 + 9.9 + 9.1 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14RPM International Inc.RPM 50.2/100Thin evidence · provisional58% evidence TURNING 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence 12.7/25 ROCE 4.8% · OPM 5% 76% evidence 11.0/20 P/E 20.5× · PEG — 15% evidence 8.2/20 RS sector -8.3% · RS bench -5.8% · 1Y -3.8%1 of 12 weeks ahead 100% evidence
Exact sum: 18.3 + 12.7 + 11 + 8.2 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15PPG Industries, Inc.PPG 50.2/100Thin evidence · provisional58% evidence TURNING 16.8/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence 12.8/25 ROCE 3.6% · OPM 13.8% 76% evidence 11.3/20 P/E 17.4× · PEG — 15% evidence 9.3/20 RS sector -5.7% · RS bench -3.5% · 1Y 10.1%3 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 12.8 + 11.3 + 9.3 = 50.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Element Solutions IncESI 49.8/100Thin evidence · provisional58% evidence ASLEEP 17.7/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence 10.6/25 ROCE 2.3% · OPM 13.3% 76% evidence 8.8/20 P/E 64.5× · PEG — 15% evidence 12.7/20 RS sector 6.6% · RS bench 8.2% · 1Y 62.7%7 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 10.6 + 8.8 + 12.7 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Linde plcLIN 47.5/100Thin evidence · provisional58% evidence ASLEEP 18.8/35 Revenue — · PAT — · OPM change 0.9 pp 45% evidence 14.3/25 ROCE 3.6% · OPM 27.8% 76% evidence 9.7/20 P/E 33.5× · PEG — 15% evidence 4.7/20 RS sector -10.3% · RS bench -8.3% · 1Y 2.6%0 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.3 + 9.7 + 4.7 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Ecolab Inc.ECL 46.7/100Thin evidence · provisional58% evidence TURNING 17.0/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence 12.9/25 ROCE 3.5% · OPM 15.3% 76% evidence 9.5/20 P/E 37.4× · PEG — 15% evidence 7.3/20 RS sector -9% · RS bench -6.6% · 1Y 3.8%1 of 12 weeks ahead 100% evidence
Exact sum: 17 + 12.9 + 9.5 + 7.3 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Cabot CorporationCBT 46.3/100Mixed-negative evidence81% evidence ASLEEP 8.9/35 Revenue -8.5% · PAT -31.2% · OPM change -3 pp 83% evidence 13.3/25 ROCE 4.5% · OPM 14.3% 76% evidence 16.5/20 P/E 14.2× · PEG 0.18 65% evidence 7.6/20 RS sector -5.2% · RS bench -3.1% · 1Y 5%8 of 12 weeks ahead 100% evidence
Exact sum: 8.9 + 13.3 + 16.5 + 7.6 = 46.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
20Air Products and Chemicals, Inc.this pageAPD 43.7/100Thin evidence · provisional58% evidence BASING 17.0/35 Revenue — · PAT — · OPM change 103.5 pp 45% evidence 9.5/25 ROCE -5.8% · OPM 23.7% 76% evidence 10.1/20 P/E 30.7× · PEG — 15% evidence 7.1/20 RS sector -7% · RS bench -4.9% · 1Y 2.1%0 of 12 weeks ahead 100% evidence
Exact sum: 17 + 9.5 + 10.1 + 7.1 = 43.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Calumet, Inc.CLMT 41.5/100Mixed-negative evidence64% evidence BREAKING OUT 9.4/35 Revenue -0.1% · PAT — · OPM change -11.7 pp 62% evidence 3.0/25 ROCE -9.1% · OPM -16.6% 76% evidence 10.3/20 P/E 30.3× · PEG — 15% evidence 18.8/20 RS sector 40.5% · RS bench 42% · 1Y 189.2%9 of 12 weeks ahead 100% evidence
Exact sum: 9.4 + 3 + 10.3 + 18.8 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 42%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
22Perimeter Solutions, Inc.PRM 40.4/100Thin evidence · provisional58% evidence FADING 10.0/35 Revenue — · PAT — · OPM change -50 pp 45% evidence 7.5/25 ROCE -7.6% · OPM 58% 76% evidence 9.0/20 P/E 53.3× · PEG — 15% evidence 13.9/20 RS sector 7.8% · RS bench 10.3% · 1Y 84.7%10 of 12 weeks ahead 100% evidence
Exact sum: 10 + 7.5 + 9 + 13.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23DuPont de Nemours, Inc.DD 38.9/100Mixed-negative evidence81% evidence BASING 22.2/35 Revenue 4% · PAT 40.7% · OPM change 5.2 pp 83% evidence 7.5/25 ROCE 0.7% · OPM 11.1% 76% evidence 4.3/20 P/E 45.4× · PEG 4.12 65% evidence 4.9/20 RS sector -21.8% · RS bench -19.3% · 1Y -32.4%0 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 7.5 + 4.3 + 4.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Albemarle CorporationALB 38.3/100Thin evidence · provisional53% evidence ASLEEP 20.0/35 Revenue — · PAT — · OPM change 14.5 pp 32% evidence 9.2/25 ROCE 1.6% · OPM 16.3% 76% evidence 9.1/20 P/E 47.9× · PEG — 15% evidence 0.0/20 RS sector -22.9% · RS bench -21.8% · 1Y 60.1%0 of 12 weeks ahead 100% evidence
Exact sum: 20 + 9.2 + 9.1 + 0 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Hawkins, Inc.HWKN 37.8/100Thin evidence · provisional58% evidence ASLEEP 14.8/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence 12.7/25 ROCE 4.4% · OPM 8.8% 76% evidence 9.4/20 P/E 41.9× · PEG — 15% evidence 0.9/20 RS sector -22.8% · RS bench -20.8% · 1Y -24.6%1 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 12.7 + 9.4 + 0.9 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26LyondellBasell Industries N.V.LYB 33.4/100Adverse evidence71% evidence ASLEEP 13.1/35 Revenue -9.4% · PAT -164.8% · OPM change 1.8 pp 83% evidence 6.5/25 ROCE 0.9% · OPM 3.3% 76% evidence 8.6/20 P/E 76.1× · PEG — 15% evidence 5.2/20 RS sector -5.6% · RS bench -4.2% · 1Y 24.6%2 of 12 weeks ahead 100% evidence
Exact sum: 13.1 + 6.5 + 8.6 + 5.2 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27The Chemours CompanyCC 28.8/100Adverse evidence64% evidence ASLEEP 12.7/35 Revenue 0.6% · PAT -3836.4% · OPM change -2 pp 62% evidence 4.4/25 ROCE 0.5% · OPM 1.9% 76% evidence 8.5/20 P/E 225.5× · PEG — 15% evidence 3.2/20 RS sector -7.7% · RS bench -6.6% · 1Y 47.1%5 of 12 weeks ahead 100% evidence
Exact sum: 12.7 + 4.4 + 8.5 + 3.2 = 28.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Westlake CorporationWLK 26.1/100Adverse evidence64% evidence BASING 9.8/35 Revenue -8.6% · PAT -473.1% · OPM change -5.4 pp 62% evidence 4.7/25 ROCE -1% · OPM -6.5% 76% evidence 9.6/20 P/E 33.6× · PEG — 15% evidence 2.0/20 RS sector -17.5% · RS bench -16.2% · 1Y 2.1%0 of 12 weeks ahead 100% evidence
Exact sum: 9.8 + 4.7 + 9.6 + 2 = 26.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Solstice Advanced Materials, Inc.SOLS 46.2/100Thin evidence · provisional36% evidence ASLEEP 12.4/35 Revenue — · PAT — · OPM change -4.5 pp 39% evidence 15.1/25 ROCE 9.6% · OPM 16.5% 76% evidence 8.7/20 P/E 67.2× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —1 of 12 weeks ahead 0% evidence
Exact sum: 12.4 + 15.1 + 8.7 + 10 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Air Products and Chemicals, Inc.'s stock price today?

Air Products and Chemicals, Inc. trades at $295, +4.6% over the past year. The company is valued at $66.0 B. The stock sits at 74% of its 52-week range of $240–$314, +6.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 2 weeks in. — as of 5 August 2026.

What were Air Products and Chemicals, Inc.'s latest quarterly results?

Air Products and Chemicals, Inc. reported revenue of $3.2 B and net profit of $0.7 B for the Mar 26 quarter. Earnings per share were $3.19. The operating margin was 23.7%, 103.5 pp higher than a year earlier. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s revenue?

Air Products and Chemicals, Inc. reported revenue of $3.2 B in the Mar 26 quarter, +8.6% year on year. For the full FY25 fiscal year, revenue was $12.0 B (−0.5%). Over the last 4 years revenue compounded at 3.9% a year. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s profit?

Air Products and Chemicals, Inc. earned $0.7 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.3 B. The operating margin ran 23.7% in the latest quarter. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s market cap?

Air Products and Chemicals, Inc.'s market capitalisation is $66.0 B at a stock price of $295. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s P/E ratio?

Air Products and Chemicals, Inc. trades at a P/E of 31.1×, at the 74th percentile of its own 4-year range, against a long-run median of 27.4×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Air Products and Chemicals, Inc. pay a dividend?

Yes — Air Products and Chemicals, Inc. declared $1.81 per share for Mar 26, and $7.18 per share across the last four reported quarters. The latest quarter is up 1.1% on the same quarter a year earlier. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s dividend per share?

Air Products and Chemicals, Inc.'s most recently declared dividend is $1.81 per share for Mar 26, giving $7.18 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s dividend yield?

Air Products and Chemicals, Inc.'s trailing dividend yield is 2.44%: $7.18 declared per share across the last four reported quarters, against a share price of $295. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

Is Air Products and Chemicals, Inc. overvalued?

On its own history, Air Products and Chemicals, Inc. looks expensive against its own history: its P/E of 31.1× sits at the 74th percentile of its 4-year range (long-run median 27.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.

How is Air Products and Chemicals, Inc. performing?

Air Products and Chemicals, Inc. is in a confirmed uptrend, 2 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Air Products and Chemicals, Inc. in?

Mixed — the growth curves are steadily positive, but ROCE at 6.4% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +3.6% latest, profit growth +36.1% latest, eps growth +37.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Air Products and Chemicals, Inc. in an uptrend?

Yes — the price is in a confirmed uptrend (week 2 of stage 2), trading +6.6% versus its 200-day average and at 74% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Air Products and Chemicals, Inc. beating the market?

Not lately — on a trailing-13-week view Air Products and Chemicals, Inc. is currently behind the S&P 500 (14 weeks and counting; last ahead the week of 2026-05-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +104% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will Air Products and Chemicals, Inc.'s stock price go up?

This page publishes no price forecast for Air Products and Chemicals, Inc. What it measures instead: the stock price is $295, the price is in a confirmed uptrend 2 weeks in. Its P/E of 31.1× sits at the 74th percentile of its own 4-year range. — as of 5 August 2026.

Is the market betting against Air Products and Chemicals, Inc.?

No — short interest is 1.9% of Air Products and Chemicals, Inc.'s tradable float, about 2.6 days to cover at typical volumes. That is a low reading: the crowd is not positioned against this stock. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Air Products and Chemicals, Inc. have too much debt?

It carries real leverage — Air Products and Chemicals, Inc.'s debt-to-equity is 1.10. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s capex?

Air Products and Chemicals, Inc. spent $18.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $7.0 B. — as of 5 August 2026.

What is Air Products and Chemicals, Inc.'s cash flow?

Air Products and Chemicals, Inc. generated $3.3 B of operating cash flow in FY25 and $−3.8 B of free cash flow after $7.0 B of capital spending. Reported profit that year was $−0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Air Products and Chemicals, Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 119% of Air Products and Chemicals, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $3.3 B against reported profit of $−0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Air Products and Chemicals, Inc.?

On the balance sheet, the Z-score reads 2.40 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is Air Products and Chemicals, Inc. in its business cycle?

Air Products and Chemicals, Inc.'s FY25 operating margin was −7.3%, against a 5-year band of −7.3%–36.9%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 23.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Air Products and Chemicals, Inc. story?

The sharpest disagreement: the price moved +4.6% in a year while annual EPS moved −110.3% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Air Products and Chemicals, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Air Products and Chemicals, Inc.'s price has outrun its earnings. +4.6% in a year against EPS −110.3% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI